Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$155,693
in 6 filings

Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-02-17 Yu Tony VP, Clinical Trial Operations Grant or award +9,000 159,000
2023-02-17 Cappello Joseph VP, Pharmaceutical Development Grant or award +9,000 9,000
2023-01-30 Szalay Aladar 10% owner Conversion +500,000 2,258,760
2023-01-30 Szalay Aladar 10% owner Conversion +500,000 550,000
2023-01-30 Szalay Aladar 10% owner Conversion · Series A Preferred Stock −1,500,000 0
2023-01-30 Szalay Aladar 10% owner Conversion · Series A Preferred Stock −1,500,000 0
2023-01-30 Thomas John Director Conversion +470,000 470,000
2023-01-30 Thomas John Director Conversion · Series A Preferred Stock −1,410,000 0
2023-01-30 Woodward Gabe Director Conversion +5,378 5,378
2023-01-30 Woodward Gabe Director Conversion +3,186 3,186
2023-01-30 Woodward Gabe Director Conversion +2,798 2,798
2023-01-30 Woodward Gabe Director Conversion · Series I Preferred Stock −13,000 0
2023-01-30 Woodward Gabe Director Conversion · Series J Preferred Stock −7,000 0
2023-01-30 Woodward Gabe Director Conversion · Series K Preferred Stock −6,000 0
2023-01-26 Zhang Qian Associate VP, Research Purchase +200 $6.25 $1K 200

Page 16 of 16 · 315 trades